Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Astrazeneca Plc (AZN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
FDA Nods to AstraZeneca's Tagrisso for First-Line NSCLC (revised)

Tagrisso is approved in the United States, European Union, Japan and China as second-line treatment for patients with advanced NSCLC.

AZN : 35.12 (-1.13%)
RHHBY : 27.9200 (+0.14%)
PFE : 37.06 (+0.71%)
BMY : 51.58 (+1.34%)
Pharma Stock Roundup: NVS, JNJ Q1 Sales & Earnings Top, MRK & BMY Active at AACR

Novartis (NVS) and J&J (JNJ) deliver strong Q1 results. Merck (MRK) and Bristol Myers (BMY) present lung cancer data at AACR.

AZN : 35.12 (-1.13%)
JNJ : 126.19 (-0.50%)
MRK : 60.09 (-0.27%)
AGN : 156.90 (-1.87%)
NVS : 76.99 (-0.79%)
RHHBY : 27.9200 (+0.14%)
BMY : 51.58 (+1.34%)
FDA Nods to AstraZeneca's Tagrisso for First-Line NSCLC

AstraZeneca (AZN) wins the FDA approval for the label expansion of its marketed drug, Tagrisso, for first-line treatment of adult patients with locally-advanced or metastatic NSCLC.

AZN : 35.12 (-1.13%)
RHHBY : 27.9200 (+0.14%)
PFE : 37.06 (+0.71%)
BMY : 51.58 (+1.34%)
Model N Founder & CEO Zack Rinat Named Ernst & Young 2018 Entrepreneur of the Year Semifinalist

Model N, Inc. (NYSE: MODN), the leading provider of revenue management solutions for the pharmaceutical, medical device, high tech, manufacturing and semiconductor industries, announced that...

ABT : 58.31 (-0.90%)
AZN : 35.12 (-1.13%)
STX : 58.27 (+0.09%)
NXPI : 101.71 (-1.42%)
MODN : 17.15 (-1.72%)
AMD : 10.09 (+0.50%)
MU : 47.11 (-3.90%)
GILD : 72.72 (-1.74%)
STM : 21.31 (+1.67%)
PFE : 37.06 (+0.71%)
SNY : 39.75 (-0.50%)
Merck's Keytruda Reduces Death Risk in Melanoma Patients

Merck's (MRK) Keytruda significantly prolongs RFS and reduces the risk of disease recurrence or death by 43% versus placebo in a phase III study in high-risk stage III melanoma patients.

AZN : 35.12 (-1.13%)
MRK : 60.09 (-0.27%)
LLY : 80.09 (-0.14%)
BMY : 51.58 (+1.34%)
G1 Therapeutics Announces Initiation of Phase 1b/2 Clinical Trial of G1T38 in Combination with Tagrisso for EGFR-Mutant Non-Small Cell Lung Cancer

G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that it has initiated a Phase 1b/2 clinical trial assessing G1T38, its oral CDK4/6 inhibitor, in combination with...

AZN : 35.12 (-1.13%)
GTHX : 38.87 (-0.66%)
Spectrum Pharma Stock Up on Positive Lung Cancer Study Data

Spectrum Pharmaceuticals' (SPPI) poziotinib shows encouraging results in preliminary analysis of data from phase II lung cancer study.

SPPI : 17.34 (-5.04%)
PTGX : 8.84 (-0.90%)
CATB : 1.64 (-0.61%)
AZN : 35.12 (-1.13%)
Ionis (IONS) Clinches Licensing Agreement with AstraZeneca

Ionis (IONS) inks a licensing deal with AstraZeneca per which the former will license IONIS-AZ6-2.5-LRx to AstraZeneca for the treatment of NASH.

LGND : 161.77 (-3.26%)
AZN : 35.12 (-1.13%)
IONS : 45.33 (-10.59%)
BMY : 51.58 (+1.34%)
Top Analyst Reports for Microsoft, Merck & Union Pacific

Top Analyst Reports for Microsoft, Merck & Union Pacific

MSFT : 93.12 (-2.34%)
COL : 133.03 (unch)
AZN : 35.12 (-1.13%)
UNP : 132.83 (-2.35%)
MRK : 60.09 (-0.27%)
SCHW : 54.49 (-1.59%)
Clovis' (CLVS) Rubraca Gets FDA Nod as Maintainence Therapy

Clovis Oncology (CLVS) announces the FDA has granted label expansion of Rubraca to include maintenance treatment of ovarian cancer patients in second line setting, irrespective of BRCA mutation status....

AZN : 35.12 (-1.13%)
CLVS : 46.26 (-4.34%)
TSRO : 53.02 (+2.00%)
PFE : 37.06 (+0.71%)
Ionis and AstraZeneca Advance New Drug for NASH

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that it has licensed IONIS-AZ6-2.5-LRx, or AZD2693, to AstraZeneca (NYSE: AZN) following advancement of...

AZN : 35.12 (-1.13%)
IONS : 45.33 (-10.59%)
Ionis and AstraZeneca Advance New Drug for NASH

CARLSBAD, Calif. , April 9, 2018 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that it has licensed IONIS-AZ6-2.5-L Rx , or...

AZN : 35.12 (-1.13%)
IONS : 45.33 (-10.59%)
Pharma Stock Roundup: LLY's Cyramza Shines in Cancer Study, PFE & AZN in Focus

Pfizer (PFE) inks new CAR-T deal, AstraZeneca (AZN) provides positive regulatory updates and Lilly's (LLY) Cyramza shows survival benefit in liver cancer study

AZN : 35.12 (-1.13%)
MRK : 60.09 (-0.27%)
LLY : 80.09 (-0.14%)
AGN : 156.90 (-1.87%)
PFE : 37.06 (+0.71%)
GSK : 40.64 (+0.77%)
BMY : 51.58 (+1.34%)
Pfizer's Lung Cancer Candidate Gets FDA's Priority Review

Pfizer's (PFE) regulatory application for dacomitinib gets accepted in the United States under priority review for non-small cell lung cancer. The EU also accepts the filing for the same indication.

AZN : 35.12 (-1.13%)
MRK : 60.09 (-0.27%)
RHHBY : 27.9200 (+0.14%)
PFE : 37.06 (+0.71%)
3 Emerging Technologies Set to Transform the Pharma World

Here we discuss three emerging technologies, which the pharma/biotech industry has started adopting, albeit slowly. These are poised to transform the sector by saving time as well as cost.

IBM : 145.56 (-0.21%)
AZN : 35.12 (-1.13%)
JNJ : 126.19 (-0.50%)
NVS : 76.99 (-0.79%)
RHHBY : 27.9200 (+0.14%)
PFE : 37.06 (+0.71%)
GSK : 40.64 (+0.77%)
Allergan's Vraylar Meets Endpoints in Bipolar I Phase III

Allergan (AGN) along with partner Gedeon Richter posts positive top-line results from the third pivotal study, analyzing label expansion of the schizophrenia drug Vraylar to cure bipolar I depression.

AZN : 35.12 (-1.13%)
JNJ : 126.19 (-0.50%)
AGN : 156.90 (-1.87%)
ALKS : 44.37 (-1.79%)
AstraZeneca's (AZN) Bydureon Gets FDA Nod for Expanded Use

AstraZeneca's (AZN) Bydureon gets FDA approval for expanded use in type II diabetes patients. Meanwhile, regulatory submissions for its leukemia candidate and Lynparza get acceptance in the United States...

AZN : 35.12 (-1.13%)
JNJ : 126.19 (-0.50%)
MRK : 60.09 (-0.27%)
CLVS : 46.26 (-4.34%)
Aeglea Initiates Lung Cancer Combination Study With Keytruda

Aeglea BioTherapeutics (AGLE) doses first patients in two early stage lung cancer studies evaluating pegzilarginase as single agent and in combination with Merck's Keytruda.

AGLE : 8.28 (+4.81%)
AZN : 35.12 (-1.13%)
MRK : 60.09 (-0.27%)
ABBV : 91.36 (-1.94%)
US FDA Approves BYDUREON for Use with Basal Insulin in Patients with Type 2 Diabetes with Inadequate Glycemic Control

AstraZeneca today announced the US Food and Drug Administration (FDA) has approved BYDUREON(R) (exenatide extended-release) for injectable suspension as an add-on therapy to basal insulin...

AZN : 35.12 (-1.13%)
US FDA Accepts Biologics License Application for Moxetumomab Pasudotox in Hairy Cell Leukemia

AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the US Food and Drug Administration (FDA) has accepted the Biologics License Application...

AZN : 35.12 (-1.13%)

Van Meerten Stock Picks

5 Great Mid Caps
This morning I wanted to find the Mid Cap stocks that not only had some of the best returns in the past 12 months but still seemed to have some upside potential.
IBKR -1.19 , HFC +1.31 , ABMD -11.72 , CAR +0.05 , URBN -0.19
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.
Free Commodities Newsletter

Get prepared for your trading day with

Barchart's Commodity Futures Morning Update Email

InsideFutures Commentary

InsideFutures weekly newsletter features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Friday morning to your inbox.

Brugler Ag Report

Today's Commentary

Corn futures closed the day with 1 to 2 3/4 cent gains. Progress along the Corn Belt was well below the average, with IA still at 0%, IL at 4%, and NE at 2% planted. TX was the only of the 18 states reported to show progress above the normal pace. Pr...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar